Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Ideal body weight correlates better with engraftment after PBSC autograft than actual body weight, but is under-estimated in myeloma patients possibly due to disease-related height loss

Bone Marrow Transplantation volume 40, pages 665–669 (2007)Cite this article

Abstract

Stem cell dose is important in determining rate of engraftment following autograft. We show closer correlation with haematopoietic reconstitution when the CD34+ cell dose is calculated using ideal (IBW) rather than actual (ABW) body weight in 218 patients receiving peripheral blood stem cell (PBSC) autograft for haematological malignancy. ABW was 21% greater than IBW thus the median CD34+ dose of 5.0 × 106/kg (ABW) rose to 6.1 × 106/kg when calculated by IBW. Neutrophils reached 0.5 × 109/l in 11 days (range 8–21), while platelets reached 20 × 109/l unsupported in 12 days (range 7–38). For both neutrophil and platelet engraftment, a greater inverse correlation was seen when IBW was used to calculate stem cell dose (r2=0.082 vs r2=0.104 for neutrophils and r2=0.085 vs r2=0.135 for platelets). Those non-myeloma patients who failed to achieve a CD34+ dose of 4 × 106 cells/kg by ABW but did so by IBW achieved neutrophil and platelet engraftment not significantly different from those who achieved that stem cell dose by both methods. This was not confirmed in patients treated for myeloma, possibly owing to inaccurate IBW in patients with skeletal height loss. We confirm that calculation of CD34+ cell dose by IBW safely predicts engraftment for patients with haematological malignancies other than myeloma undergoing PBSC autograft.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Bensinger WI, Longin K, Appelbaum F, Rowley S, Weaver C, Lilleby K et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825–831.

    Article  CAS  Google Scholar 

  2. Shpall EJ, Champlin R, Glaspy JA . Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998; 4: 84–92.

    Article  CAS  Google Scholar 

  3. Ali MY, Oyama Y, Monreal J, Winter JN, Tallman MS, Williams SF et al. Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation? Bone Marrow Transplant 2003; 31: 861–864.

    Article  CAS  Google Scholar 

  4. Cilley J, Rihn C, Monreal J, Gordon LI, Singhal S, Tallman M et al. Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopoietic stem cell transplantation? Bone Marrow Transplant 2004; 33: 161–164.

    Article  CAS  Google Scholar 

  5. Waples JM, Moreb JS, Sugrue M, Belanger G, Kubilis P, Lynch JW et al. Comparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight. Bone Marrow Transplant 1999; 23: 867–873.

    Article  CAS  Google Scholar 

  6. Singhal S, Gordon LI, Tallman MS, Winter JN, Evens AO, Frankfurt O et al. Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation [erratum appears in Bone Marrow Transplant. 2006 Jun;37(11):1067 Note: Evens, AO [corrected to Evens, AM]]. Bone Marrow Transplant 2006; 37: 553–557.

    Article  CAS  Google Scholar 

  7. Gratama JW, Kraan J, Keeney M, Sutherland DR, Granger V, Barnett D et al. Validation of the single-platform ISHAGE method for CD34(+) hematopoietic stem and progenitor cell enumeration in an international multicenter study. Cytotherapy 2003; 5: 55–65.

    Article  CAS  Google Scholar 

  8. Devine DJ . Gentamicin therapy. Drug Intell Clin Pharm 1974; 8: 650–655.

    Article  Google Scholar 

  9. Hirani V . Chapter 5: Anthropometric Measures, Overweight, and Obesity. In: Bromley C, Sproston K, Shelton N (eds). The Scottish Health Survey 2003. Volume 2: Adults. www.scotland.gov.uk, 2005.

  10. Brincker H, Westin J, Abildgaard N, Gimsing P, Turesson I, Hedenus M et al. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish–Swedish co-operative study group. Br J Haematol 1998; 101: 280–286.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Apheresis, Scottish National Blood Transfusion Service, Glasgow Royal Infirmary, Scotland, UK

    P S Maclean & K W Douglas

  2. Bone Marrow Transplant Unit, Glasgow Royal Infirmary, Scotland, UK

    A N Parker, I G McQuaker, A D Clark & E Farrell

Authors
  1. P S Maclean
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A N Parker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I G McQuaker
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A D Clark
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E Farrell
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K W Douglas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P S Maclean.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maclean, P., Parker, A., McQuaker, I. et al. Ideal body weight correlates better with engraftment after PBSC autograft than actual body weight, but is under-estimated in myeloma patients possibly due to disease-related height loss. Bone Marrow Transplant 40, 665–669 (2007). https://doi.org/10.1038/sj.bmt.1705789

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705789

Keywords

This article is cited by

Search

Advanced search

Quick links